Lipidor Reports Update on Patient Enrolment in P-III Clinical Study of AKP02 for the Treatment of Mild to Moderate Psoriasis

Published: May 20, 2022 | Tags: Lipidor, P-III, AKP02, Psoriasis

Mustang Bio Provides Updates of MB-107 in the P-I/II study for the Treatment of X-Linked Severe Combined Immunodeficiency

Published: May 20, 2022 | Tags: Mustang Bio, MB-107, P-I/II Study, X-Linked Severe Combined Immunodeficiency

Calliditas Receives CHMP Positive Opinion of Kinpeygo for the Treatment of Primary Immunoglobulin A Nephropathy

Published: May 20, 2022 | Tags: Calliditas, CHMP, Kinpeygo, Primary Immunoglobulin A Nephropathy

Abbott Presents Results of TriClip Device and Navitor TAVI System for Tricuspid Regurgitation & Aortic Stenosis at EuroPCR 2022

Published: May 20, 2022 | Tags: Abbott, TriClip Device, Navitor TAVI System, Tricuspid Regurgitation, Aortic Stenosis, EuroPCR, 2022

Zealand Reports Results of Dasiglucagon in P-III (17103) Trial for the Treatment of Congenital Hyperinsulinism in Pediatric Patients

Published: May 20, 2022 | Tags: Zealand, Dasiglucagon, P-III, 17103 Trial, Congenital Hyperinsulinism

Mirati Submits MAA to the EMA for Adagrasib (MRTX849) to Treat KRASG12C-Mutated Non-Small Cell Lung Cancer

Published: May 20, 2022 | Tags: Mirati, MAA, EMA, Adagrasib, KRASG12C-Mutated, Non-Small Cell Lung Cancer

Active Biotech’ Tasquinimod Receives the US FDA’s Orphan Drug Designation for the Treatment of Myelofibrosis

Published: May 19, 2022 | Tags: Active Biotech, Tasquinimod, US, FDA, Orphan Drug Designation, Myelofibrosis

Rocket Presents Results of RP-L201 in the P-II Trial for the Treatment of Severe Leukocyte Adhesion Deficiency-I at ASGCT 2022

Published: May 19, 2022 | Tags: Rocket, RP-L201, P-II Trial, Severe Leukocyte Adhesion Deficiency-I, ASGCT, 2022

IO Biotech Reports First Patient Dosing of IO102-IO103 + Keytruda (pembrolizumab) in the P-III (IOB-013 / KN-D18) Trial as 1L Treatment of Advanced Melanoma

Published: May 19, 2022 | Tags: IO Biotech, IO102-IO103, Keytruda, pembrolizumab, P-III, IOB-013, KN-D18 Trial, Melanoma

Axsome Reports Results of AXS-05 in the P-II (ASCEND) Study for the Treatment of Major Depressive Disorder

Published: May 19, 2022 | Tags: Axsome, AXS-05, P-II, ASCEND Study, Major Depressive Disorder

Evotec Collaborated with Almirall to Discover and Develop Novel Therapies for the Treatment of Skin Diseases

Published: May 19, 2022 | Tags: Evotec, Almirall, Novel Therapies, Skin Diseases, EVOiR&D Platform

Scilex Reports the Initiation of SP-103 in P-II Study for the Treatment of Acute Low Back Pain

Published: May 19, 2022 | Tags: Scilex, SP-103, P-II Study, Acute Low Back Pain

Teleflex’s MANTA Vascular Closure Device Receives Health Canada Approval for Large Bore Femoral Arterial Access Site Closure

Published: May 18, 2022 | Tags: Teleflex, MANTA Vascular Closure Device, Health Canada, Approval, Large Bore Femoral Arterial, Site Closure

4D Pharma Presents Results of MRx-4DP0004 in P-I/II Trial for the Treatment of Asthma at ATS 2022

Published: May 18, 2022 | Tags: 4D Pharma, MRx-4DP0004, P-I/II Trial, Asthma, ATS, 2022

Idera Stops P-II (INTRIM 1) Trial of Tilsotolimod (IMO-2125) Due to Positive Efficacy in Patients with Melanoma

Published: May 18, 2022 | Tags: Idera, P-II, INTRIM 1 Trial, Tilsotolimod, IMO-2125, Melanoma

Ultragenyx Entered into an Exclusive License Agreement with Abeona for ABO-102 (UX111) to Treat Sanfilippo Syndrome Type A

Published: May 18, 2022 | Tags: Ultragenyx, Abeona, ABO-102, UX111, Sanfilippo Syndrome Type A

Pfizer and BioNTech Report EUA Expansion for Booster Dose of COVID-19 Vaccine in Children Aged 5 Through 11 Years

Published: May 18, 2022 | Tags: Pfizer, BioNTech, EUA, Booster Dose, COVID-19, Vaccine

LifeArc Co-Founded Company RQ Bio Entered into a License Agreement with AstraZeneca to Develop Monoclonal Antibodies Against SARS-CoV-2

Published: May 18, 2022 | Tags: LifeArc, RQ Bio, AstraZeneca, Monoclonal Antibodies, SARS-CoV-2

MannKind Entered into an Agreement with Zealand to Acquire V-Go Insulin Delivery Device for the Treatment of Diabetes

Published: May 17, 2022 | Tags: MannKind, Zealand, Acquire, V-Go, Insulin Delivery Device, Diabetes

Evotec Collaborated with Sernova to Develop iPSC-Based Beta Cell Replacement Therapy for the Treatment of Diabetes

Published: May 17, 2022 | Tags: Evotec, Sernova, iPSC-Based, Beta Cell Replacement Therapy, Diabetes

Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy

Published: May 17, 2022 | Tags: Travere Therapeutics, US, FDA, NDA, Priority Review, Sparsentan, IgA Nephropathy

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -901) Trial as 1L Treatment for Unresectable or Metastatic Urothelial Carcinoma

Published: May 17, 2022 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, P-III, CheckMate -901 Trial, Urothelial Carcinoma

AbbVie Signs an Exclusive Worldwide License Option Agreement with Cugene for CUG252 to Treat Autoimmune Diseases

Published: May 17, 2022 | Tags: AbbVie, Option Agreement, Cugene, CUG252, Autoimmune Diseases

Proteros Expands 2021 Agreement with AstraZeneca to Develop Epigenetic Therapies for the Treatment of Cancer

Published: May 17, 2022 | Tags: Proteros, 2021, AstraZeneca, Epigenetic Therapies, Cancer

Emergent BioSolutions Entered into a Definitive Agreement with Chimerix to Acquire Tembexa (brincidofovir) Rights for Smallpox

Published: May 16, 2022 | Tags: Emergent BioSolutions, Chimerix, Acquire, Tembexa, brincidofovir, Smallpox

KemPharm Signs a Definitive Agreement with Orphazyme to Acquire Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Published: May 16, 2022 | Tags: KemPharm, Orphazyme, Acquire, Arimoclomol, Niemann-Pick Disease Type C

Sanofi Presents Results of Sarclisa (isatuximab) in P-III (IKEMA) Trial for Relapsed Multiple Myeloma at COMy 2022

Published: May 16, 2022 | Tags: Sanofi, Sarclisa, isatuximab, P-III, IKEMA Trial, Relapsed Multiple Myeloma

Lilly's Mounjaro (tirzepatide) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes

Published: May 16, 2022 | Tags: Lilly, Mounjaro, tirzepatide, US, FDA, Approval, Type 2 Diabetes

AstraZeneca Reports Results of PT027 in a P-III (MANDALA) Trial as a Fixed-Dose Combination of Albuterol and Budesonide for Asthma

Published: May 16, 2022 | Tags: AstraZeneca, PT027, P-III, MANDALA Trial, Albuterol, Budesonide, Asthma

Urovant Presents Interim Results of URO-902 in P-IIa Study for the Treatment of Overactive Bladder at AUA 2022

Published: May 16, 2022 | Tags: Urovant Sciences, URO-902, P-IIa Study, Overactive Bladder, AUA, 2022

Related Post: PharmaShots Weekly Snapshots (May 09-13, 2022)